Brief: Tarsus Pharmaceuticals Reports Qtrly Loss Per Share $0.24
11/08/2022 22:28
Aug 11 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O :
* TARSUS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND
RECENT
BUSINESS ACHIEVEMENTS
* CASH RUNWAY ANTICIPATED INTO AT LEAST 2026 FOR COMMERCIAL
LAUNCH
OF TP-03 AND CONTINUED PIPELINE DEVELOPMENT
* QTRLY LOSS PER SHARE $0.24
* Q2 EARNINGS PER SHARE VIEW $-0.59 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX2XcDJC
Further company coverage: TARS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)